Acceptability of contraceptive implants at the maternity ward of the Matam Communal Medical Center

Background: World Health Organization (WHO), defines contraception as "the use of agents, devices, methods or procedures to decrease the likelihood of conception or avoid it". In Africa, only 24% of women of childbearing age have access to a modern contraceptive method. The objective of the study was to determine the frequency of use of the contraceptive implant, to describe the socio-demographic characteristics of the users, to identify the reasons for the choice of the method and to assess the degree of satisfaction of the clients.Methods: The study was conducted at the Matam Communal Medical Center on level 2 of the health pyramid in Guinea. This was a 12-month cross-sectional, descriptive and analytical study (June 2017 to May 2018), including all women admitted for desire for contraception and who agreed to choose the implant as a contraceptive method.Results: The study involved 512 clients. The proportion of female users was 26.21%. The average age was 27.8 years, the main users were women of liberal trade, married, multiparous. The main reasons for choice cited by clients were the effectiveness and long duration of action of the method, i.e. 35.2% and 30.9% respectively. The majority of providers of the method were represented by midwives (73.3%) and the degree of client satisfaction with the method was 97%.Conclusions: The implant is a long-acting method of contraction. It is frequently used at the Communal Medical Center of Matam. Its efficient use would involve effective counselling

Amniotic band syndrome: a new case report

Amniotic band syndrome is a pathology affecting the extremities of the fetus. It is uncommon with rates around 1 per 10,000 births. The pathophysiology is poorly understood until now with several theories reported in the literature. The diagnosis is most often made at birth. We reported a case of a 40 year old patient with no particular history who had consulted for spontaneous premature rupture of membranes in a 20 weeks pregnancy. The diagnostic of amniotic band syndrome was made after the delivery with amputation of a limb, amniotic syndactilia and deformation of the right foot in equinovarus

Puerperal uterine inversion: a new case report

Puerperal uterine inversion is a rare and severe affection which the uterine fundus collapses into the endometrial cavity. The diagnosis is essentially made on clinical examination, which also allows to determinate the gravity. The management must be done early, which can be surgical or non-surgical. Through a case study we will review the literature

L’usage des arts pour le dialogue environnemental au Sahel

L’art a été utilisé pour communiquer les préoccupations environnementales dans les pays sahéliens. Néanmoins, le dialogue dirigé par les arts entre les acteurs politiques et les citoyens est cependant rare, bien qu’il ait le potentiel de trouver des solutions aux problèmes socio-environnementaux complexes. Il est indispensable d’exploiter ce potentiel, alors que des défis, tels que le changement climatique, s’accélèrent et touchent les populations. La sensibilisation aux processus de dialogue menés par les arts pourrait être renforcée, parallèlement à davantage de recherches sur les contextes dans lesquelles ils sont appropriés et sur la meilleure façon de les utiliser.This IDS Policy Briefing contains an English summary and recommendations on page 4. Art has been used to communicate environmental concerns in Sahelian countries. Nevertheless, arts-led dialogue between policy actors and citizens is rare, despite its potential to find solutions to complex socio-environmental problems. Harnessing this potential is essential as challenges such as climate change accelerate. Factors that constrain dialogue include a strongly hierarchical and sectorally divided professional and social context. Artists and citizens also risk confrontation with authorities when they express controversial opinions. Not every situation is therefore appropriate for arts-led dialogue. Yet, when facilitated with humour and effective examples, it can create a relaxed space for intersectoral deliberation. Awareness of arts-led dialogue processes could be increased, along with more research on the contexts in which they are appropriate and how best to use them.Arts and Humanities Research Counci

Efficacy and tolerability of a new formulation of artesunate-mefloquine for the treatment of uncomplicated malaria in adult in Senegal: open randomized trial

BACKGROUND: Prompt treatment of malaria attacks with arteminisin-based combination therapy (ACT) is an essential tool for malaria control. A new co-blister tablet of artesunate-mefloquine (AM) with 25 mg/kg mefloquine has been developed for the management of uncomplicated malaria attacks. This non-inferiority randomized trial, was conducted to evaluate the efficacy and safety of the new formulation of AM in comparison to artemether-lumefantrine (AL) for the treatment of acute uncomplicated Plasmodium falciparum malaria in adults in Senegal. METHODS: The study was carried out from September to December 2010 in two health centres in Senegal. The study end points included (i) PCR corrected adequate clinical and parasitological response (ACPR) at day 28, (ii) ACPR at days 42 and 63, (iii) parasites and fever clearance time, (iv) incidence of adverse events and patients biological profile at day 7 using the WHO 2003 protocol for anti-malarial drug evaluation. RESULTS: Overall, 310 patients were randomized to receive either AM (n = 157) or AL (n = 153). PCR corrected ACPR at day 28 was at 95.5% in the AM arm while that in the AL arm was at 96.7% (p = 0.83). Therapeutic efficacy was at 98.5% in the AM arm versus 98.2% in the AL group at day 42 (p = 1). At day 63, ACPR in the AM and AL arms was at 98.2% and 97.7%, respectively (p = 0.32). The two treatments were well tolerated with similar biological profile at day 7. However, dizziness was more frequent in the AM arm. CONCLUSION: Artesunate-mefloquine (25 mg/Kg mefloquine) is efficacious and well-tolerated for the treatment of uncomplicated P. falciparum malaria in adult patients

Monitoring the efficacy and safety of three artemisinin based-combinations therapies in Senegal: results from two years surveillance

BACKGROUND: Malaria remains a major public health problem in developing countries. Then in these countries prompt access to effective antimalarial treatment such as Artemisinin based-Combination Therapies (ACT) proves to be an essential tool for controlling the disease. In Senegal, since 2006 a nationwide scaling up program of ACT is being implemented. In this context it has become relevant to monitor ACT efficacy and provide recommendations for the Senegalese national malaria control program. METHODS: An open randomized trial was conducted during two malaria transmission seasons (2011 and 2012) to assess the efficacy and safety of three combinations: dihydro-artemisinin-piperaquine (DHAPQ), artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ). The primary end point of the study was represented by a PCR adjusted adequate clinical and parasitological response (ACPR) at day 28. Secondary end points included: (i) a ACPR at days 35 and 42, (ii) a parasite and fever clearance time, (iii) ACTs safety and tolerability. The 2003 WHO’s protocol for antimalarial drug evaluation was used to assess each outcome. RESULTS: Overall, 534 patients were randomized selected to receive, either ASAQ (n = 180), AL (n = 178) or DHAPQ (n = 176). The PCR adjusted ACPR at day 28 was 99.41% for the group ASAQ, while that was 100% in the AL and DHAPQ groups (p = 0.37). The therapeutic efficacy was evaluated at 99.37% in the ASAQ arm versus 100% in AL and DHAPQ arm at day 35 (p = 0.37). At day 42, the ACPR was 99.27% in the ASAQ group versus 100% for both AL and DHAPQ groups, (p = 0.36). No serious adverse event was noted during the study period. Also a similar safety profile was noted in the 3 study groups. CONCLUSION: In the context of scaling up of ACTs in Senegal, ASAQ, AL and DHAPQ are highly effective and safe antimalarial drugs. However, it’s remains important to continue to monitor their efficacy. TRIAL REGISTRATION: PACTR 201305000552290